EYPT registers up to $200,000,000 in common stock via supplement

Rhea-AI Filing Summary

EyePoint Pharmaceuticals filed a prospectus supplement covering the registered offering of up to $200,000,000 of common stock pursuant to its Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. The supplement relates to the company’s effective Form S-3 (File No. 333-290867), which became automatically effective upon filing.

The company also filed a legal opinion from Hogan Lovells US LLP validating the Shares, included as Exhibit 5.1. This filing provides a framework to sell shares as needed under the existing sales agreement, offering flexibility to access capital subject to market conditions.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001314102 0001314102 2025-11-06 2025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 6, 2025

EyePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		000-51122		26-2774444
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

480 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices, and Zip Code)

(617) 926-5000

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		EYPT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On November 6, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) to its effective registration statement on Form S-3 (File No. 333-290867) (the “Registration Statement”), filed with the U.S. Securities and Exchange Commission on October 14, 2025, which became automatically effective upon filing, covering the registered offering of up to $200,000,000 of shares of common stock, par value $0.001 per share, of the Company (the “Shares”), pursuant to the Controlled Equity Offering^SM Sales Agreement (the “Sales Agreement”), dated August 5, 2020, with Cantor Fitzgerald & Co.

In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Hogan Lovells US LLP, relating to the validity of the Shares being registered, which opinion is attached as Exhibit 5.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
1.1		Controlled Equity OfferingSM Sales Agreement, dated August 5, 2020, by and between EyePoint Pharmaceuticals, Inc. and Cantor Fitzgerald & Co. (incorporated by reference to Exhibit No 1.1 to the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 5, 2020)
5.1		Opinion of Hogan Lovells US LLP
23.1		Consent of Hogan Lovells US LLP (contained in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				EYEPOINT PHARMACEUTICALS, INC.
Date: November 6, 2025				By:		/s/ George O. Elston
				Name:		George O. Elston
				Title		Executive Vice President and Chief Financial Officer

FAQ

What did EYPT announce in its 8-K?

EyePoint filed a prospectus supplement to register the offering of up to $200,000,000 of common stock under its Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co.

Which registration statement does this supplement relate to for EYPT?

It relates to Form S-3, File No. 333-290867, which became automatically effective upon filing.

What securities can EYPT offer under the supplement?

Shares of common stock, par value $0.001 per share, up to an aggregate offering amount of $200,000,000.

Who is the sales agent for EYPT’s offering?

Cantor Fitzgerald & Co. under the Controlled Equity OfferingSM Sales Agreement dated August 5, 2020.

Did EYPT include a legal opinion with the filing?

Yes. A Hogan Lovells US LLP opinion on the validity of the Shares was filed as Exhibit 5.1.

When was the prospectus supplement filed by EYPT?

On November 6, 2025.